A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis
Authors:
- Liliana Eleonora SemenescuLSLiliana Eleonora Semenescu
- Ligia Gabriela TataranuLTLigia Gabriela Tataranu
- Anica DricuADAnica Dricu
- Gheorghe Vasile CiubotaruGCGheorghe Vasile Ciubotaru
- Mugurel Petrinel RadoiMRMugurel Petrinel Radoi
- Silvia Mara Baez RodriguezSRSilvia Mara Baez Rodriguez
- Amira KamelAKAmira Kamel
Open Access
- 7 September 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2485
Abstract
Background: While acknowledging the generally poor prognostic features of brain metastases from renal cell carcinoma (BM RCC), it is important to be aware of the fact that neurosurgery still plays a vital role in managing this disease, even though we have entered an era of targeted therapies. Notwithstanding their initial high effectiveness, these agents often fail, as tumors develop resistance or relapse. Methods: The authors of this study aimed to evaluate patients presenting with BM RCC and their outcomes after being treated in the Neurosurgical Department of Clinical Emergency Hospital “Bagdasar-Arseni”, and the Neurosurgical Department of the National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania. The study is based on a thorough appraisal of the patient’s demographic and clinicopathological data and is focused on the strategic role of neurosurgery in BM RCC. Results: A total of 24 patients were identified with BM RCC, of whom 91.6% had clear-cell RCC (ccRCC) and 37.5% had a prior nephrectomy. Only 29.1% of patients harbored extracranial metastases, while 83.3% had a single BM RCC. A total of 29.1% of patients were given systemic therapy. Neurosurgical resection of the BM was performed in 23 out of 24 patients. Survival rates were prolonged in patients who underwent nephrectomy, in patients who received systemic therapy, and in patients with a single BM RCC. Furthermore, higher levels of hemoglobin were associated in our study with a higher number of BMs. Conclusion: Neurosurgery is still a cornerstone in the treatment of symptomatic BM RCC. Among the numerous advantages of neurosurgical intervention, the most important is represented by the quick reversal of neurological manifestations, which in most cases can be life-saving.Keywords
Funding Information
- UEFISCDI (PN-III-P4-ID-PCE-2020-1649)
This publication has 93 references indexed in Scilit:
- Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapyActa Oncologica, 2012
- Pattern of declining hemoglobin concentration before cancer diagnosisInternational Journal of Cancer, 2010
- Imaging renal cell carcinoma with ultrasonography, CT and MRINature Reviews Urology, 2010
- Surgical management of lateral-ventricle metastases: report of 29 cases in a single-institution experienceJournal of Neurosurgery, 2010
- Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapyBJU International, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- COMPARATIVE RISK OF LEPTOMENINGEAL DISSEMINATION OF CANCER AFTER SURGERY OR STEREOTACTIC RADIOSURGERY FOR A SINGLE SUPRATENTORIAL SOLID TUMOR METASTASISNeurosurgery, 2009
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990